Analyst consensus rating
Taysha Gene Therapies Analyst Rating: Strong Buy
TSHA is rated Strong Buy by 12 analysts with a $13.33 target. As of 2026-09-02.
Direct answer
Taysha Gene Therapies's consensus rating is Strong Buy.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $13.33.
Forecast evidence checked September 2, 2026.
Get free Taysha Gene Therapies email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $5.57
- Average price target
- $13.33
- High price target
- $19.00
- Low price target
- $10.00
- Low target gap
- +79.7%
- Target upside
- +139.6%
- High target gap
- +241.4%
- Target range width
- 161.7%
- Consensus rating
- Strong Buy
- Analysts
- 12
- Evidence date
- September 2, 2026
- Valid through
- September 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Taysha Gene Therapies?
Taysha Gene Therapies has a verified Strong Buy consensus. The same dataset has an average price target of $13.33.
How far are Taysha Gene Therapies's low and high targets from the recorded price?
The low target implies +79.7%, while the high target implies +241.4%.
How many analysts are included in Taysha Gene Therapies's consensus?
The verified consensus includes 12 analysts.
How is Taysha Gene Therapies's target upside or downside calculated?
The average target of $13.33 is divided by the recorded price of $5.57, then one is subtracted to produce +139.6%. This does not guarantee a future return.
When was Taysha Gene Therapies's analyst forecast verified?
The data was verified on 2026-09-02. The dataset is valid through 2026-09-09.